Table 1—

Patient characteristics, clinical behavior, and glycemic burden by treatment

Diet and exerciseSulfonylurea monotherapyMetformin monotherapySulfonylurea and metformin combination therapy
n2,3193,394513982
Age (years)57.7 ± 12.255.7 ± 11.855.5 ± 11.657.8 ± 11.4
Men (%)52.652.548.552.6
Duration of diabetes (years)0.00.6 ± 1.32.0 ± 2.34.3 ± 2.3
BMI (k/m2)34.1 ± 7.234.4 ± 7.434.9 ± 7.734.6 ± 7.8
Last HbA1c before treatment (%)9.6 ± 2.18.8 ± 1.89.2 ± 1.7
First HbA1c on treatment (%)7.4 ± 1.57.6 ± 1.58.2 ± 1.88.4 ± 1.5
Best HbA1c on treatment (%)7.2 ± 1.47.1 ± 1.47.7 ± 1.67.7 ± 1.3
Mean HbA1c on treatment (%)7.9 ± 1.38.2 ± 1.38.4 ± 1.58.8 ± 1.2
Last HbA1c on treatment (%)8.6 ± 1.69.1 ± 1.78.8 ± 1.79.6 ± 1.7
Months on treatment29.8 ± 14.735.1 ± 17.826.5 ± 13.533.9 ± 16.9
No. of HbA1c tests4.0 ± 2.85.8 ± 4.04.3 ± 3.26.6 ± 4.5
HbA1c tests >8.0% (%)35.548.749.666.6
Months HbA1c >8.0%8.7 ± 12.520.5 ± 18.014.5 ± 13.725.6 ± 17.2
Total glycemic burden (months)
 Base HbA1c 8.0%8.6 ± 22.419.4 ± 31.817.0 ± 25.829.9 ± 35.6
 Base HbA1c 7.0%22.5 ± 32.041.5 ± 43.433.5 ± 34.758.3 ± 46.2
Avoidable burden (months)
 Base HbA1c 8.0%4.4 ± 14.816.5 ± 28.312.3 ± 21.326.0 ± 30.6
 Base HbA1c 7.0%15.8 ± 24.636.6 ± 39.625.9 ± 30.151.1 ± 41.6
Subsequent therapy (proportions)
 Sulfonylurea0.7360.916
 Metformin0.2260.913
 Other oral agent0.0030.0150.0210.123
 Insulin0.0360.0710.0620.877
 Total1.0001.0001.0001.000
Switched after HbA1c first exceeded 8.0% or before (% subjects)66.635.344.618.6
  • Data are means ± SD, unless noted otherwise.